MARKET

EYPT

EYPT

EyePoint
NASDAQ
12.50
-0.56
-4.29%
After Hours: 12.50 0 0.00% 17:20 03/27 EDT
OPEN
12.95
PREV CLOSE
13.06
HIGH
13.12
LOW
12.44
VOLUME
843.54K
TURNOVER
--
52 WEEK HIGH
19.11
52 WEEK LOW
3.910
MARKET CAP
1.04B
P/E (TTM)
-3.9473
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at EYPT last week (0316-0320)?
Weekly Report · 5d ago
EyePoint sues Ocular over claims related to lead asset
Seeking Alpha · 03/21 14:23
EyePoint Sues Ocular Therapeutix Over Alleged Defamation
TipRanks · 03/20 21:04
EyePoint Files Lawsuit Against Ocular Therapeutix Alleging Defamation And Misleading Claims Over DURAVYU Clinical Results
Benzinga · 03/20 20:39
EYEPOINT INC - COMPLAINT ASSERTS DEFAMATION, COMMERCIAL DISPARAGEMENT, AND TORTIOUS INTERFERENCE CLAIMS - SEC FILING
Reuters · 03/20 20:35
EyePoint sues Ocular Therapeutix over alleged false statements about DURAVYU clinical results
Reuters · 03/20 20:34
Revolution, Ascendis, Arrowhead among RBC’s top M&A candidates in biotech
Seeking Alpha · 03/19 18:37
Top Executive Makes Bold Insider Move at EyePoint Pharmaceuticals
TipRanks · 03/17 02:04
More
About EYPT
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.

Webull offers EyePoint Inc stock information, including NASDAQ: EYPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EYPT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EYPT stock methods without spending real money on the virtual paper trading platform.